ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2886

Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries

Emily Somers1, Lu Wang 2, W Joseph McCune 3, S Sam Lim 4, Cristina Drenkard 4, Elizabeth Ferucci 5, Maria Dall'Era 6, Caroline Gordon 7, Charles Helmick 8, Hilary Parton 9 and Peter Izmirly 10, 1University of Michigan Schools of Medicine & Public Health, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Ann Arbor, MI, 4Emory University, Atlanta, GA, 5Alaska Native Tribal Health Consortium, Anchorage, AK, 6University of California, San Francisco, San Francisco, CA, 7University of Birmingham, Birmingham, United Kingdom, 8Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, 9New York City Department of Health & Mental Hygiene, Long Island City, NY, 10NYU School of Medicine, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: epidemiologic methods and meta-analysis, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

Session Type: ACR Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: The heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) and lack of a diagnostic test make SLE difficult for epidemiologists to study. The Centers for Disease Control and Prevention (CDC) supported five population-based SLE surveillance registries, using harmonized methodology, to better estimate incidence and prevalence of SLE in diverse areas in the United States (US). Leveraging these data, we performed a meta-analysis to estimate the general prevalence of SLE in the US.

Methods: The CDC registries were established in Michigan, Georgia, California, New York and the through the Indian Health Service (IHS).  All registries used the 1997 revised ACR classification criteria for SLE as their primary case definition, and the surveillance time periods ranged from 2003 to 2009. Age-standardized prevalence was stratified by sex and race/ethnicity from the state-based registries; the American Indian/Alaska Native (AI/AN) estimate was based on the IHS registry that covered multiple states.  For pooling data across the four sites with data on different racial/ethnic groups, we used Cochran’s Q and I² statistic to test for heterogeneity across sites. Due to significant heterogeneity, we used a random effects model to calculate pooled prevalence, which allows for more variation across sites.   We then extrapolated to the 2017 Census population data according to sex and race-stratified groups, including data from the IHS registry, and summed the stratum-specific estimates to provide a total population estimate of SLE cases in the US.

Results: The registries contributed 5,417 classified cases of SLE from a mix of urban and rural areas. From the meta-analysis of the four state-based registries, the overall prevalence was 72.8 (95%CI 65.3, 81.0) per 100,000 population. The prevalence among females was about 9 times higher than males (128.7 vs 14.6). In the meta-analysis, prevalence was highest among black females (230.9, 95%CI 178.2, 299.2), followed by Hispanic females (120.7, 95%CI 84.0, 173.4), white females (84.7, 95%CI 68.4, 104.8) and Asian/Pacific Islander females (84.4, 95%CI 48.3, 147.4). Among males, prevalence followed a similar pattern with the highest rates among black males (26.7, 95%CI 19.6, 36.4) followed by Hispanic males (18.0, 95%CI 15.6, 20.8), Asian/Pacific Islander males (11.2, 95%CI 5.7, 21.9), and white males (8.9, 95%CI 8.0, 10.1). The AI/AN prevalence estimates, which were not included in the meta-analysis, had the highest rates of SLE for both females (271, 95%CI 238, 307) and males (54, 95%CI 36, 77). Applying our sex- and race-specific prevalence estimates to the corresponding population denominators from 2017 Census data, we estimated that 198,677 persons (179,186 females and 19,491 males) in the US fulfill ACR SLE classification criteria, Table 1.

Conclusion: Using estimates from a coordinated network of population-based SLE registries, a more accurate prevalence estimate for the US was obtained. Our methods did not capture undiagnosed, “incomplete”, or other forms of lupus such as cutaneous lupus. Other case definitions may yield different results.


TableAbsv4caption


Disclosure: E. Somers, None; L. Wang, None; W. McCune, None; S. Lim, None; C. Drenkard, None; E. Ferucci, None; M. Dall'Era, Biogen,, 5, Genentech, 5, Janssen Pharmaceuticals, 5, Kezar Life Sciences, 2, Pfizer, 5; C. Gordon, Bristol-Myers Squibb, 5, 8, Centers for Disease Control and Prevention, 5, Eli Lilly, 5, 8, EMD Serono, 5, EMD Serono, UCB, 5, GlaxoSmithKline, 5, 8, Merck Serono, 5, 8, UCB, 2, 5, 8, Versus Arthritis/GSK, 2; C. Helmick, None; H. Parton, None; P. Izmirly, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Somers E, Wang L, McCune W, Lim S, Drenkard C, Ferucci E, Dall'Era M, Gordon C, Helmick C, Parton H, Izmirly P. Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-systemic-lupus-erythematosus-in-the-united-states-preliminary-estimates-from-a-meta-analysis-of-the-centers-for-disease-control-and-prevention-lupus-registries/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-systemic-lupus-erythematosus-in-the-united-states-preliminary-estimates-from-a-meta-analysis-of-the-centers-for-disease-control-and-prevention-lupus-registries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology